Development milestones

This is an interim progress update as of September 10, 2026, not completion of a final formulation or a canine clinical study. Aqueous solubility, particle size and stability still require verification. Cell-based findings do not establish effectiveness in dogs.

The date records contract execution, not the start of dosing, study completion or regulatory approval. Subsequent study records will substantiate progress and findings.

This TF-15 study was not GLP regulatory toxicology or a long-term safety study. It does not establish safety in dogs, for purified Antcin A or for a final product.

A cooperation and licensing framework does not establish drug approval, efficacy, safety or commercial outcomes.

This is the start of the project period specified in the agreement, not evidence that every study began on that date or has been completed. Safety, toxicology, residue and formulation-standardization work remains underway; the completed report and regulatory conclusions are still pending.

Study initiation is not study completion. This preliminary design cannot be extrapolated to canine or long-term safety.

December 12, 2025 is the public-report date, not a statutory completion or agency-review date. At this stage the Ministry was informed of progress but had not formally reviewed or accepted these materials; formal review occurs only after the complete application package is submitted. The headline’s “phase one” is not a human Phase I trial.

The patent protects cultivation and carrier technology; it does not establish TFA-01 efficacy, safety or drug approval.

The report itself characterizes the work as preliminary and calls for batch reproducibility and further study. It does not establish direct receptor binding, formal synergy, a steroid-sparing effect, canine or human clinical efficacy, or drug approval.

This was a forward-looking plan. It does not mean an application was submitted or accepted, required studies were completed, or a drug was approved.

The public material describes preliminary cell work and does not independently establish synergy, a steroid-sparing effect, direct receptor mechanism or clinical efficacy.

This milestone marks the company’s first self-directed drug-related industry-academia project entering its formal project period. It does not mean the mechanism was fully proven, direct receptor binding was established, canine or human clinical efficacy was confirmed, or a drug was approved.